Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Clinical Trial

Official title:
A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

Status Terminated

Clinical Trial Summary

A phase 1/2 study to assess the safety and efficacy of MB-102 in patients with relapsed or refractory BPDCN

Clinical Trial Description

The Phase 1 portion of the study will determine the maximum tolerated dose of MB-102. The Phase 2 portion of the trial will evaluate the efficacy of MB-102 in relapsed or refractory BPDCN. ;

Study Design

Related Conditions & MeSH terms

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Neoplasms

Clinical Trial Details

NCT number	NCT04109482
Study type	Interventional
Source	Mustang Bio
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	February 17, 2020
Completion date	May 17, 2023

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05645744` - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Completed	`NCT02113982` - SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia	Phase 1/Phase 2
Active, not recruiting	`NCT04013685` - Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies	Phase 1
Active, not recruiting	`NCT03599960` - Combination Chemotherapy in Patients With Newly Diagnosed BPDCN	Phase 2
Terminated	`NCT03203369` - Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN	Phase 1
Recruiting	`NCT05430971` - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Recruiting	`NCT06006403` - Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm	Phase 1/Phase 2